Literature DB >> 9264369

Cranial irradiation is the major cause of learning problems in children treated for leukemia and lymphoma: a comparative study.

J E Van Dongen-Melman1, A De Groot, J J Van Dongen, F C Verhulst, K Hählen.   

Abstract

Prophylactic treatment of the central nervous system (CNS) in childhood leukemia and non-Hodgkin lymphoma (NHL) has negative effects on intelligence. We investigated the clinical significance of this finding by comparing the effect of different types of CNS prophylaxis on the survivor's learning capabilities. To isolate the effect of different types of CNS prophylaxis from other treatment and disease variables on learning problems, children treated for leukemia or NHL who received CNS prophylaxis with cranial irradiation (n = 30) or without cranial irradiation (n = 36) were compared with children treated for solid tumors who received systemic chemotherapy without any CNS treatment (n = 30) and with matched healthy controls (n = 265). The identification of learning problems was based on the school system's assessment. Parents and teachers reported on the child's educational status in a standardized way. Learning problems were found in 80% of children who received CNS prophylaxis with cranial irradiation. This was significantly higher than the 14% found in children treated with CNS prophylaxis without cranial irradiation (P < 0.000). The prevalence of learning problems in this latter group did not differ significantly from that in childhood cancer survivors without any form of CNS prophylaxis (20%) and in healthy matched controls (17%). We conclude that the high prevalence of learning problems in survivors of childhood leukemia and NHL is directly related to CNS prophylaxis with cranial irradiation and not to CNS prophylaxis per se or to other treatment and disease variables.

Entities:  

Mesh:

Year:  1997        PMID: 9264369     DOI: 10.1038/sj.leu.2400702

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  8 in total

Review 1.  Poor school performance.

Authors:  Sunil Karande; Madhuri Kulkarni
Journal:  Indian J Pediatr       Date:  2005-11       Impact factor: 1.967

2.  [CNS irradiation in pediatric acute myeloid leukemia. No reduction in effectiveness upon dose reduction from 18 to 12 Gy].

Authors:  I Ernst; H T Eich
Journal:  Strahlenther Onkol       Date:  2013-07       Impact factor: 3.621

3.  Human embryonic stem cell-derived oligodendrocyte progenitors remyelinate the brain and rescue behavioral deficits following radiation.

Authors:  Jinghua Piao; Tamara Major; Gordon Auyeung; Edelweiss Policarpio; Jayanthi Menon; Leif Droms; Philip Gutin; Kunihiro Uryu; Jason Tchieu; Denis Soulet; Viviane Tabar
Journal:  Cell Stem Cell       Date:  2015-02-05       Impact factor: 24.633

Review 4.  Radioprotection.

Authors:  Joel S Greenberger
Journal:  In Vivo       Date:  2009 Mar-Apr       Impact factor: 2.155

5.  Leukemias and lymphomas: treatment and prophylaxis of the central nervous system.

Authors:  Janet L Franklin; Jonathan Finlay
Journal:  Curr Treat Options Neurol       Date:  2006-07       Impact factor: 3.972

6.  Neurocognitive outcome in survivors of childhood acute lymphoblastic leukemia: experience at a tertiary care hospital in Korea.

Authors:  Seong Joon Kim; Min Hyun Park; Jae Wook Lee; Nak Gyun Chung; Bin Cho; In Goo Lee; Seung Yun Chung
Journal:  J Korean Med Sci       Date:  2015-03-19       Impact factor: 2.153

7.  Association between (GT)n Repeats in Heme Oxygenase-1 Gene Promoter and 3-Year Survival of Patients with Acute Leukemia: a Controlled, Cross-Sectional Study.

Authors:  Mohammad Kazemi; Farinaz Khosravian; Amir Abbas Sameti; Alireza Moafi; Mohammad Reza Merasi; Mansour Salehi; Majid Nejati; Mohaddeseh Behjati
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2018-01-01

8.  Educational attainment among survivors of childhood cancer: a population-based cohort study in Denmark.

Authors:  S V Koch; A M T Kejs; G Engholm; C Johansen; K Schmiegelow
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.